Lithium: Understanding Your Blood Test Series

1. Overview: What this test reveals and why it is important

Lithium is a monovalent cation and the lightest alkali metal, used for over seven decades as the gold standard mood stabiliser in psychiatry. It remains the most effective long-term treatment for bipolar disorder, significantly reducing the risk of both manic and depressive episodes, and is the only psychotropic medication consistently shown to reduce suicide mortality in mood disorders. It is also used as augmentation therapy in treatment-resistant unipolar depression and, off-label, for conditions such as cluster headache prophylaxis.

Unlike the nutritional elements discussed in previous guides, lithium is a therapeutic drug with no known essential biological function in humans. Its narrow therapeutic index – the margin between ineffective, therapeutic, and toxic levels – is exceptionally slim. Serum lithium concentrations must be maintained within a specific target range to achieve clinical efficacy while avoiding potentially irreversible toxicity.

Measuring serum lithium levels serves several critical purposes:

· Establishing therapeutic dosing: Initial titration to achieve target range

· Monitoring adherence: Objective assessment of compliance

· Preventing toxicity: Early detection of rising levels before symptoms appear

· Investigating suspected toxicity: Confirming diagnosis in patients presenting with compatible symptoms

· Guiding perioperative management: Ensuring safety during surgery when fluid shifts and medications alter lithium clearance

Lithium is not protein-bound, is freely filtered by the glomerulus, and 80% is reabsorbed in the proximal tubule in competition with sodium. This close relationship with sodium and renal function underpins both its pharmacokinetics and its toxicity profile. The test must always be interpreted in conjunction with clinical status, renal function, electrolyte balance, and concurrent medications.

---

2. What does it measure

a. Units of measurement

· Serum lithium concentration: Millimoles per litre (mmol/L) or milliequivalents per litre (mEq/L). These units are numerically equivalent for lithium.

· Timing is critical: Samples must be drawn 12 hours (± 30 minutes) after the last dose (trough level), immediately prior to the next scheduled dose. This ensures steady-state measurement and consistency for interpretation.

b. Normal range and therapeutic targets

Reference ranges are indication-specific and vary by age, clinical context, and guideline. The following are representative based on international guidelines:

Bipolar disorder – maintenance: 0.6 – 0.8 mmol/L (some guidelines 0.5–0.8)

Bipolar disorder – acute mania: 0.8 – 1.2 mmol/L

Bipolar disorder – acute depression: 0.8 – 1.2 mmol/L (as monotherapy)

Unipolar depression – augmentation: 0.4 – 0.8 mmol/L (often 0.4–0.6)

Older adults (≥65 years): 0.4 – 0.8 mmol/L (lower end for maintenance)

Older adults ≥80 years: 0.4 – 0.7 mmol/L

Critical interpretive principles:

· Toxicity generally occurs at levels >1.5 mmol/L, though symptoms may appear at lower levels in vulnerable individuals (elderly, dehydrated, those on interacting medications).

· Some patients exhibit toxicity at "therapeutic" levels (<1.0 mmol/L), particularly if levels rise rapidly or if they are unusually sensitive.

· Conversely, some patients require levels at the higher end of the range for full protection; individualisation is essential.

· Never interpret lithium level in isolation. Always assess alongside clinical status, renal function (creatinine, eGFR), electrolytes (sodium, potassium), and thyroid function.

---

3. Other factors connected to this

a. Direct correlation (factors that increase serum lithium levels / toxicity risk)

· Dehydration: Reduced renal perfusion increases proximal tubular reabsorption of lithium. Any cause – vomiting, diarrhoea, fever, hot weather, inadequate fluid intake – can precipitate toxicity.

· Sodium depletion: Low sodium intake (salt restriction, diuretics) enhances lithium reabsorption in the proximal tubule.

· Reduced glomerular filtration rate (GFR): Acute kidney injury, chronic kidney disease, or age-related decline reduce lithium clearance.

· Medications that increase lithium levels:

· Thiazide diuretics: Increase proximal reabsorption; can raise lithium levels by 25–40%.

· Non-steroidal anti-inflammatory drugs (NSAIDs): Reduce GFR; all NSAIDs except aspirin and sulindac affect lithium.

· ACE inhibitors and angiotensin receptor blockers (ARBs): Reduce GFR and alter sodium handling.

· Metronidazole, tetracyclines: Case reports of increased levels.

· Calcium channel blockers (verapamil, diltiazem): Possible interaction.

· Selective serotonin reuptake inhibitors (SSRIs): May increase levels via unclear mechanisms.

· Concurrent lithium formulations: Different brands have different bioavailability; always prescribe by brand name and avoid switching without monitoring.

b. Indirect correlation (factors influencing lithium requirements or toxicity risk independently of serum level)

· Age: Elderly patients have reduced GFR and lower total body water; they achieve higher serum levels at lower doses and are more susceptible to neurotoxicity.

· Pregnancy: GFR increases during pregnancy, lowering lithium levels; dramatic postpartum drop in GFR can precipitate toxicity if dose not reduced.

· Surgery and perioperative period: Fasting, fluid shifts, blood loss, and intravenous fluids alter lithium clearance. Guidelines recommend temporary discontinuation before major surgery.

· Nephrogenic diabetes insipidus (NDI): Affects 20–40% of long-term lithium users. Polyuria (≥3 L/day) causes chronic fluid loss, increasing toxicity risk if fluid intake is inadequate.

· Intercurrent illness: Infections, gastroenteritis, and any condition causing vomiting, diarrhoea, or fever increase toxicity risk.

· Weight and body composition: Lithium distributes in total body water; lower lean mass (e.g., sarcopenia in elderly) reduces volume of distribution.

· Genetic factors: Polymorphisms in genes affecting renal transport may influence lithium handling.

---

4. Disorders related to abnormal values

a. When low (subtherapeutic levels)

· Inadequate dosing: Failure to achieve target range.

· Non-adherence: Very common; serum level <0.2 mmol/L suggests complete non-adherence.

· Increased clearance: Pregnancy, hypervolaemia, lithium-wasting states (rare).

· Drug interactions that lower lithium: Theophylline, caffeine (high doses), acetazolamide, mannitol – increase renal excretion.

Clinical consequences of subtherapeutic levels:

· Breakthrough manic or depressive episodes

· Increased risk of relapse in bipolar disorder

· Loss of suicide-protective effect

b. When high (lithium toxicity)

Lithium toxicity is a medical emergency. Severity correlates with level and chronicity, but clinical presentation guides management.

Mild to moderate toxicity (typically 1.5 – 2.5 mmol/L):

· Gastrointestinal: Nausea, vomiting, diarrhoea

· Neuromuscular: Fine tremor (becomes coarse), muscle weakness, fasciculations, ataxia, dysarthria, nystagmus

· Neuropsychiatric: Drowsiness, lethargy, confusion, cognitive slowing

Severe toxicity (typically >2.5 mmol/L):

· Neurological: Seizures, coma, obtundation, hyperreflexia, extrapyramidal signs, cerebellar dysfunction (ataxia, dysarthria), choreoathetosis

· Cardiovascular: QT prolongation, T wave changes, sinoatrial block, bradycardia, hypotension, arrhythmias

· Pulmonary: Rare but described – acute non-cardiogenic pulmonary oedema, ARDS

· Nephrological: Acute kidney injury, polyuria (if NDI present)

Chronic toxicity: Often insidious, presenting with subtle cognitive impairment, tremor, ataxia, and progressive renal impairment. Patients may tolerate moderately elevated levels without acute symptoms but accumulate long-term damage.

Syndrome of Irreversible Lithium-Effectuated Neurotoxicity (SILENT): Rare but devastating complication where cerebellar and brainstem dysfunction (ataxia, dysarthria, nystagmus, cognitive impairment) persists despite lithium discontinuation. More common after acute-on-chronic toxicity.

Causes of elevated levels:

· Excessive dose (therapeutic misadventure or intentional overdose)

· Dehydration / intercurrent illness

· Drug interactions (NSAIDs, thiazides, ACE inhibitors)

· Renal impairment

· Intentional overdose (acute or acute-on-chronic)

---

5. Best way to address aberrant levels

Critical principle: Lithium is a medication, not a nutrient. It must be prescribed, monitored, and adjusted only by qualified healthcare professionals. Never self-adjust lithium dose. If toxicity is suspected, seek immediate medical attention.

a. Medical Management of Subtherapeutic Levels

· Assess adherence: Non-adherence is common; explore barriers, educate on risks, simplify regimen if possible (once-daily dosing).

· Increase dose cautiously: Under specialist supervision. Increase by small increments (e.g., 150–300 mg daily) and recheck level after 5–7 days (steady state).

· Check timing of blood sample: Ensure sample was drawn correctly (12 hours post-dose). If drawn earlier, level will be falsely elevated; if later, falsely low.

· Re-evaluate target range: Is the current target appropriate for the indication? Some patients require higher levels for acute episodes.

· Address factors increasing clearance: Review medications (theophylline, caffeine overuse), hydration status.

b. Medical Management of Elevated Levels / Lithium Toxicity

Immediate actions (emergency department):

· Discontinue lithium immediately.

· Assess ABCs: Airway, breathing, circulation. Secure airway if consciousness impaired.

· Obtain urgent serum lithium, electrolytes, creatinine, and ECG.

· Intravenous fluids: Normal saline (0.9% sodium chloride) at 1–2 L initially, then adjusted to maintain adequate urine output and correct any dehydration. Saline enhances lithium clearance by competing for reabsorption in proximal tubule.

· Correct electrolyte imbalances: Especially sodium and potassium.

Gastrointestinal decontamination (acute ingestion):

· Gastric lavage: Only if presentation within 1 hour of ingestion and airway protected.

· Activated charcoal: Does NOT bind lithium; not effective. However, consider if co-ingestants present.

· Whole bowel irrigation (polyethylene glycol): May be considered for extended-release formulations or large ingestions, as lithium tablets can remain in gut for prolonged periods.

· Sodium polystyrene sulfonate (SPS): Controversial; may bind lithium in gut, but hypokalaemia and intestinal necrosis reported. Not routine. Newer cation exchangers (sodium zirconium cyclosilicate) under investigation.

Enhanced elimination:

· Haemodialysis: The most effective method for removing lithium. Indications for haemodialysis:

· Severe neurotoxicity (seizures, coma, depressed consciousness)

· Serum lithium >4.0 mmol/L in acute toxicity

· Serum lithium >2.5 mmol/L in chronic toxicity with symptoms

· Renal failure (inability to clear lithium)

· Expected time to reduce level to <1.0 mmol/L >36 hours

· Patients with significant comorbidity (heart failure, liver disease) who cannot tolerate fluid loading

· Continue haemodialysis until serum lithium <1.0 mmol/L and clinical improvement occurs. Rebound elevation common post-dialysis as lithium redistributes from tissues; repeated or continuous dialysis may be required.

· Consider transfer to facility with haemodialysis capability if not available locally.

Monitoring:

· Serial lithium levels: Every 2–4 hours initially, then less frequently as level falls.

· Frequent clinical reassessment: Neurological status, vital signs, fluid balance.

· Renal function and electrolytes: Monitor closely.

Discharge planning:

· Unintentional toxicity (dehydration, drug interaction): Once stable, levels therapeutic, and cause addressed, discharge with clear instructions to avoid precipitating factors and follow-up within 1 week.

· Intentional overdose: Psychiatric assessment required before discharge.

c. Long-Term Monitoring to Prevent Aberrant Levels

Before initiating lithium:

· Baseline serum creatinine and eGFR

· Electrolytes (sodium, potassium)

· Thyroid function tests (TSH, FT4)

· Calcium (lithium can cause hyperparathyroidism)

· ECG in those with cardiovascular risk factors

During maintenance therapy:

· Lithium level:

· Weekly until stable after initiation or dose change

· Every 3 months for first year

· Every 6 months thereafter (or every 3 months in higher-risk patients: elderly, interacting medications, renal impairment, poor control, last level >0.8 mmol/L)

· Renal function (creatinine, eGFR): Every 6 months

· Thyroid function (TSH): Every 6 months

· Calcium: At least annually

· Weight / BMI: Monitor regularly

Patient education:

· Signs of toxicity: Provide written information. Educate patient and family to recognise early symptoms: vomiting, diarrhoea, tremor, drowsiness, unsteadiness.

· Maintain adequate fluid intake: Especially during hot weather, fever, or exercise.

· Do not restrict salt intake without medical advice.

· Avoid NSAIDs (ibuprofen, diclofenac, naproxen). Use paracetamol instead.

· Inform all healthcare providers (including dentists, pharmacists) about lithium therapy.

· Check with pharmacist before taking any over-the-counter medication.

· MedicAlert bracelet or equivalent recommended.

d. Dietary and Lifestyle Considerations (Supporting Stable Lithium Levels)

Lithium is a medication, not a dietary component. However, diet and lifestyle profoundly affect lithium levels and toxicity risk. The ecological hierarchy guides food choices, but safety around lithium is paramount.

· Hydration – the single most important factor:

· Maintain consistent daily fluid intake (typically 2–3 L).

· Increase intake during hot weather, exercise, fever, or gastrointestinal illness.

· Recognise early signs of dehydration (thirst, dark urine, dizziness).

· Sodium intake:

· Maintain consistent salt intake. Do not suddenly increase or decrease salt consumption.

· Avoid crash diets, salt restriction, or "detox" diets.

· If prescribed a low-salt diet for hypertension or heart failure, this must be managed jointly with the psychiatrist; lithium dose may need adjustment.

· Note: "Pink Himalayan salt," "sea salt," and other gourmet salts contain sodium and will affect lithium similarly to table salt. Iodised salt is preferable for thyroid health (see Iodine guide).

· Caffeine:

· High doses of caffeine (coffee, energy drinks) increase lithium excretion, potentially lowering levels.

· Abrupt caffeine withdrawal can reduce excretion, increasing levels.

· Maintain consistent caffeine intake; avoid sudden changes.

· Alcohol:

· Can cause dehydration and increase toxicity risk.

· May exacerbate sedation and cognitive effects.

· Limit or avoid; discuss with psychiatrist.

· Weight management:

· Obesity is common in bipolar disorder; weight gain is a side effect of some medications (but less so with lithium).

· A plant-forward, whole-food, low-glycaemic diet supports healthy weight and cardiovascular health.

· Avoid crash diets or rapid weight loss, which can affect lithium levels.

· Foods and supplements to avoid or use cautiously:

· NSAIDs: Avoid all non-steroidal anti-inflammatory drugs. Use paracetamol (acetaminophen) for pain/fever.

· Herbal supplements: Many have uncertain effects on lithium.

· Avoid: St John's Wort (may affect mood and interact unpredictably).

· Caution with: Herbs with diuretic effects (dandelion, juniper, horsetail, parsley, uva ursi) – can increase lithium levels by reducing fluid volume.

· Caution with: Adaptogenic herbs (ashwagandha, rhodiola, ginseng) – theoretical interactions; limited safety data. Use only under specialist guidance.

· Cranberry juice/concentrate: Large amounts may affect lithium clearance; moderate intake (<200 mL daily) likely safe.

· Potassium supplements: Only if prescribed; monitor electrolytes.

· Meals and medication timing:

· Lithium can be taken with food to reduce gastric irritation.

· Taking at night (as often recommended) allows morning trough blood draw 12 hours later.

---

6. How soon can one expect improvement and the ideal time frame to retest

Lithium levels change rapidly with dose adjustment, intercurrent illness, or drug interactions.

After dose initiation or change:

· Steady state achieved after 5–7 days (approximately 5 half-lives; lithium half-life 18–36 hours).

· Check level 7 days after dose change, drawn 12 hours post-dose.

· Adjust dose by small increments and recheck until target range achieved.

After suspected toxicity:

· Emergency: Immediate level and clinical assessment.

· During treatment of toxicity: Serial levels every 2–4 hours initially, then less frequently.

· Post-dialysis: Check level immediately after dialysis and again in 6–12 hours to detect rebound.

Routine monitoring intervals (stable patient):

· First year: Every 3 months.

· Thereafter: Every 6 months (or more frequently if risk factors present).

· Renal and thyroid function: Every 6 months.

· Calcium: Annually.

Special situations requiring extra monitoring:

· Pregnancy: Check level at least monthly; more frequently near term and postpartum.

· Intercurrent illness: Check level during and after recovery if vomiting, diarrhoea, or fever.

· Addition/withdrawal of interacting medication: Check level 5–7 days after change.

· Hospitalisation or surgery: Monitor perioperatively as per risk category below.

Perioperative monitoring (based on surgical risk category):

· Low-risk surgery (no expected blood loss/fluid shifts, e.g., cataract, hernia):

· Continue lithium.

· Check level within last few months preoperatively (if stable) or repeat 1–7 days before.

· Recheck 1 week postoperatively.

· Intermediate-risk surgery (limited blood loss/fluid shifts, e.g., hip replacement, laparoscopic surgery):

· Check level 1–7 days preoperatively.

· Stop lithium evening before surgery.

· Resume 1 day after surgery if oral intake resumed, stable renal function.

· Recheck 1 week postoperatively.

· High-risk surgery (significant blood loss/fluid shifts, e.g., cardiac, major abdominal):

· Discontinue lithium 72 hours before surgery.

· Reintroduce only when haemodynamically stable, normal electrolytes, adequate oral intake.

· Monitor levels closely upon reintroduction; check 1 week after restart.

---

Conclusion

Lithium is a paradox: a simple element, yet one of the most powerful and precise tools in psychiatry. It is the gold standard against which all other mood stabilisers are measured, the only medication proven to reduce the devastatingly elevated suicide risk in bipolar disorder. Yet its therapeutic window is treacherously narrow, its pharmacokinetics easily disrupted by dehydration, drugs, or intercurrent illness. The serum lithium level is therefore not a mere number; it is a safety gauge, a compliance check, and a guide to therapy all in one. It must be drawn with ritualistic precision – 12 hours after the last dose – and interpreted in the full context of renal function, electrolytes, and clinical state. For the patient, lithium demands partnership: consistent hydration, stable salt intake, avoidance of NSAIDs, and vigilance for the earliest whispers of toxicity – vomiting, tremor, drowsiness. For the clinician, it demands meticulous monitoring and prompt response to changing levels. And for both, it offers the reward of stability – mood, life, and future preserved. Lithium teaches us that the smallest quantities carry the greatest responsibilities, and that in medicine, as in alchemy, the transformation of a simple element into healing depends entirely on precision.

---x---x

Note on dietary recommendations on this site:

For the sake of our environment we adhere to the following dietary preference hierarchy:

1. Plant‑based

2. Fungi / algae / fermented

3. Biotechnology / lab‑grown / cultures

4. Dairy / eggs

5. Meat / fish / poultry (only if no effective alternative exists)

This approach reflects ecological responsibility, antibiotic stewardship, and the urgent need to reduce the environmental footprint of dietary recommendations. For patients taking lithium, the primary dietary considerations are consistency of fluid and salt intake rather than the specific source of foods. A plant-forward, whole-food diet aligns with cardiovascular and metabolic health in bipolar disorder and can be safely followed while maintaining stable lithium levels, provided hydration and sodium intake remain consistent. Always discuss any significant dietary changes with your psychiatrist.

-x-x